Pharmanovia Obtains Sanofi’s Central Nervous System Collection
Deal features 11 brands including Frisium and Gardenal.
Pharmanovia has officially expanded its neurology arsenal with the acquisition of 11 central nervous system (CNS) brands from Sanofi. Focusing on the psycholeptic, anxiolytic, anti-epileptic and anti-psychotic therapy areas, the acquired treatments include Frisium, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren, and Castilium.
"Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium and Gardenal, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner,” said James Burt, PhD, CEO, Pharmanovia, in a company press release. “We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs.”
Reference: Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi. Business Wire. September 18, 2023. Accessed August 19, 2023. https://www.businesswire.com/news/home/20230918003077/en/Pharmanovia-Acquires-Global-Central-Nervous-System-CNS-Portfolio-From-Sanofi
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
